海吉亚医疗公告，将动用回购授权，以不时在公开市场上以不少于人民币3亿元的总价格回购本公司股 份，以实际行动传递对公司内在价值的认可和长远发展的坚定信心。未来，公司还将视市场情况，持续 优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的资本配置安排。 责任编辑：卢昱君 海吉亚医疗公告，将动用回购授权，以不时在公开市场上以不少于人民币3亿元的总价格回购本公司股 份，以实际行动传递对公司内在价值的认可和长远发展的坚定信心。未来，公司还将视市场情况，持续 优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的资本配置安排。 责任编辑：卢昱君 海吉亚医疗（06078）早盘涨超6%，截至发稿，股价上涨4.21%，现报12.12港元，成交额5223.46万港 元。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 海吉亚医疗（06078）早盘涨超6%，截至发稿，股价上涨4.21%，现报12.12港元，成交额5223.46万港 元。 ...

每经AI快讯，海吉亚医疗(06078.HK)早盘涨近6%，截至发稿，涨5.85%，报12.31港元，成交额3947.42 万港元。 ...

消息面上，海吉亚医疗公告，将动用回购授权，以不时在公开市场上以不少于人民币3亿元的总价格回 购本公司股份，以实际行动传递对公司内在价值的认可和长远发展的坚定信心。未来，公司还将视市场 情况，持续优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的资本配置安 排。 智通财经APP获悉，海吉亚医疗(06078)早盘涨超6%，截至发稿，涨5.85%，报12.31港元，成交额 3947.42万港元。 ...

海吉亚医疗(06078)早盘涨超6%，截至发稿，涨5.85%，报12.31港元，成交额3947.42万港元。 消息面上，海吉亚医疗公告，将动用回购授权，以不时在公开市场上以不少于人民币3亿元的总价格回 购本公司股份，以实际行动传递对公司内在价值的认可和长远发展的坚定信心。未来，公司还将视市场 情况，持续优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的资本配置安 排。 ...

海吉亚医疗公告将动用回购授权，以不时在公开市场上以不少于人民币3亿元的总价格回购本公司股 份，以实际行动传递对公司内在价值的认可和长远发展的坚定信心。未来，公司还将视市场情况，持续 优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的资本配置安排。 ...

Company News - China Shenhua (01088.HK) reported coal sales of 389.5 million tons for the first 11 months, a decrease of 7.7% year-on-year. November sales were 37 million tons, down 3.6% year-on-year [1] - China Metallurgical Group (01618.HK) signed new contracts worth RMB 958.13 billion in the first 11 months, an 8.6% decrease year-on-year, with overseas contracts amounting to RMB 75 billion, a 0.4% increase year-on-year [1] - China Eastern Airlines (00670.HK) saw a 6.51% year-on-year increase in passenger capacity in November, with passenger turnover up 10.35% year-on-year and a seat load factor of 87.37%, up 3.04 percentage points year-on-year [1] - China Southern Airlines (01055.HK) reported an 8.68% year-on-year increase in passenger capacity in November, with passenger turnover up 10.42% year-on-year and a seat load factor of 86.29%, up 1.36 percentage points year-on-year [1] - New China Life Insurance (01336.HK) recorded cumulative original insurance premium income of RMB 188.85 billion for the first 11 months, a 16% year-on-year increase [1] - AOS Group (01161.HK) announced annual results for the year ending September 30, 2025, with revenue of approximately HKD 981 million, a decrease of 0.19% year-on-year, and a net profit of HKD 80.887 million, a 19% year-on-year increase [1] - Hopson Development Holdings (00754.HK) reported total contract sales of approximately RMB 14.27 billion for the first 11 months, an 8.91% decrease year-on-year [1] - Agile Group (01813.HK) had a pre-sale amount of RMB 511 million in November, a decrease of 21.4% year-on-year [1] - Galen Pharmaceuticals (01672.HK) is expected to become a best-in-class oral small molecule IL-17 inhibitor, with positive topline results from its Phase I study in the U.S. [1] - Bole Technology (02592.HK) submitted a new drug clinical trial application for CBT-199 to the U.S. FDA [1] - China Supply Chain Industry (03708.HK) signed a strategic cooperation framework agreement with Golden Energy regarding digital assets [1] - Times China Holdings (01233.HK) had its liquidation petition withdrawn [1] - Botai Car Union (02889.HK) received a first project designation notice from a leading domestic new energy vehicle client [1] Buyback Activities - Haijia Medical (06078.HK) plans to repurchase 10% of its issued shares, with a repurchase amount of no less than RMB 300 million [1] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with repurchase prices ranging from HKD 602.5 to HKD 608 [1] - Xiaomi Group (01810.HK) repurchased 7.2 million shares for HKD 302 million, with repurchase prices ranging from HKD 41.78 to HKD 42 [1] Share Cancellation - Pacific Shipping (02343.HK) canceled 23.739 million repurchased shares [2]

Core Viewpoint - Haijia Medical (06078.HK) announced a general authorization for share repurchase at the upcoming annual general meeting on June 27, 2025, allowing the company to repurchase up to 61.8499 million shares, representing 10% of the total issued shares as of the meeting date [1] Group 1 - The company’s stock closed at HKD 11.63 on December 15, 2025, with an increase of 0.26% and a trading volume of 4.5822 million shares, resulting in a turnover of HKD 53.1235 million [1] - The investment banks predominantly rate the stock as a buy, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for Haijia Medical [1] Group 2 - Haijia Medical has a market capitalization of HKD 7.175 billion and ranks 7th in the medical services sector II [1] - Key performance indicators for the company are summarized in the accompanying table [1]

本公司认为，股份目前的交易价格并未反映其内在价值或本公司的实际业务前景。因此，本公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币3亿元的总价格购回股份。本公司认为，建 议股份购回将展现本公司对其自身业务发展前景充满信心，而本公司现有财务资源将足以支持实施建议 股份购回，同时维持稳健的财务状况。本公司将视市场情况，持续优化股东回报，在回购、分红及併购 扩张中做出更高效的、更有利于股东价值的资本配置安排。 海吉亚医疗(06078)发布公告，就有关本公司股东于本公司于2025年6月27日举行的股东周年大会授出的 购回本公司股份的一般授权的相关事宜。根据购回授权，本公司获准于香港联合交易所有限公司购回最 多6184.99万股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 ...

智通财经APP讯，海吉亚医疗(06078)发布公告，就有关本公司股东于本公司于2025年6月27日举行的股 东周年大会授出的购回本公司股份的一般授权的相关事宜。根据购回授权，本公司获准于香港联合交易 所有限公司购回最多6184.99万股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的 10%。 本公司认为，股份目前的交易价格并未反映其内在价值或本公司的实际业务前景。因此，本公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币3亿元的总价格购回股份。本公司认为，建 议股份购回将展现本公司对其自身业务发展前景充满信心，而本公司现有财务资源将足以支持实施建议 股份购回，同时维持稳健的财务状况。本公司将视市场情况，持续优化股东回报，在回购、分红及併购 扩张中做出更高效的、更有利于股东价值的资本配置安排。 ...

Core Viewpoint - The company believes that its current share price does not reflect its intrinsic value or actual business prospects, prompting the board to decide on a share buyback program [1] Group 1 - The company plans to utilize its buyback authorization to repurchase shares in the open market [1] - The total amount allocated for the share buyback is not less than RMB 300 million [1]